A phase‐1, open‐label, single‐dose study of the pharmacokinetics of buparlisib in subjects with mild to severe hepatic impairment

The pharmacokinetics (PK) and safety of single‐dose buparlisib (30 mg) were assessed in subjects with mild to severe hepatic impairment (n = 6 each) relative to healthy controls (n = 13). Blood samples were collected until 336 hours postdose and evaluated by liquid chromatography tandem mass spectro...

Descripción completa

Detalles Bibliográficos
Autores principales: Csonka, Denes, Hazell, Katharine, Waldron, Edward, Lorenzo, Sebastien, Duval, Vincent, Trandafir, Lucia, Kobalava, Zhanna D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Pharmacokinetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5049450/
https://www.ncbi.nlm.nih.gov/pubmed/26183800
http://dx.doi.org/10.1002/jcph.590

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5049450/
https://www.ncbi.nlm.nih.gov/pubmed/26183800
http://dx.doi.org/10.1002/jcph.590

Ejemplares similares